Microbot Medical launches Liberty robotic system in U.S.

Microbot Medical has begun full U.S. market release of its Liberty Endovascular Robotic System. The company announced the launch at the Society of Interventional Radiology Annual Scientific Meeting in Toronto.

Liberty is an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, according to Microbot. The company said the system is designed for vascular navigation while aiming to reduce radiation exposure and physical strain.

Commercial use during the limited market release included prostate artery embolization, uterine fibroid embolization, genicular artery embolization, Y90 mapping, Y90 delivery, and peripheral arterial interventions.

Microbot said the limited release included adoption by multiple healthcare systems with dozens of hospitals in their networks, including Emory Healthcare and Tampa General Hospital.

Sales coverage has expanded from 4 to 8 U.S. territories in preparation for full market release. Microbot said it aims to reach 12 territories by the end of 2026.

SIR 2026 was held April 11-15. Microbot said it planned to show the system at booth 423 and educate physicians on its capabilities during the meeting.